MP49-03 TUMOR INFILTRATING B-CELLS ARE INCREASED IN PROSTATE CANCER TISSUE

You have accessJournal of UrologyProstate Cancer: Basic Research IV1 Apr 2014MP49-03 TUMOR INFILTRATING B-CELLS ARE INCREASED IN PROSTATE CANCER TISSUE Jason Woo, Michael Liss, Michelle Muldong, Amy Strasner, Nissi Varki, Ahmed Shabaik, Stephen Howell, Christopher Kane, Michael Karin, and Christina Jamieson Jason WooJason Woo More articles by this author , Michael LissMichael Liss More articles by this author , Michelle MuldongMichelle Muldong More articles by this author , Amy StrasnerAmy Strasner More articles by this author , Nissi VarkiNissi Varki More articles by this author , Ahmed ShabaikAhmed Shabaik More articles by this author , Stephen HowellStephen Howell More articles by this author , Christopher KaneChristopher Kane More articles by this author , Michael KarinMichael Karin More articles by this author , and Christina JamiesonChristina Jamieson More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1104AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives CD20+ B-cell tumor infiltrating lymphocytes (TILs) have prognostic significance in melanoma, breast, non-small cell lung, and ovarian cancers. The presence of increased B-cell TILs has not been demonstrated in a systematic fashion in prostate cancer (CaP). Animal models have shown B-cell interactions may be a harbinger of hormone-refractory CaP. We investigate the density of B-cells within the CaP tissue utilizing a reproducible and quantitative computational method of identifying B-cells. Methods 53 paraffin-embedded radical prostatectomy specimens underwent CD20 immunohistochemical staining to identify B-cells. CaP tumors were identified and marked by a genitourinary pathologist manually (figure 1a,b). Slides were digitally scanned and a computer algorithm quantified the area of stained B-cells within the CaP and surrounding tissue (figure 1b,d). Patient clinicopathological features of each specimen were obtained. The primary outcome was B-cell density within CaP versus outside the cancer. Secondary outcome was B-cell density compared to outcomes including Gleason score, D’Amico risk groups, and recurrence. Results 8 (15.1%), 9 (17%) and 36 (67.9%) specimens were from patients with low, intermediate and high risk disease, respectively. 19 (35.8%) specimens were from any risk group with disease recurrence. For the entire cohort, the mean density (area of B-cells in mm2/area of prostate analyzed in mm2) within the tumor was higher (3.22, SE=0.29) than outside the tumor (2.24, SE=0.19) (paired t test; P<0.001). D’Amico low risk (0.0377 vs. 0.0246; p=0.151) and intermediate risk (0.0260 vs. 0.0214; p=0.579) did not show significantly more B-cells within the tumor. The high risk group (0.0301 vs. 0.0197; p<0.001) and patients who eventually had CaP recurrence (0.0343 vs. 0.0246; p=0.019) did show significantly more CD20+ B-cell staining within CaP tumors. B-cell density did not correlate to any other patient clinical parameters. Conclusions B-cells are present in higher density within CaP tissue than within benign prostate. The interaction of B-cells and CaP may serve as the basis of new therapeutic targets. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e502-e503 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Jason Woo More articles by this author Michael Liss More articles by this author Michelle Muldong More articles by this author Amy Strasner More articles by this author Nissi Varki More articles by this author Ahmed Shabaik More articles by this author Stephen Howell More articles by this author Christopher Kane More articles by this author Michael Karin More articles by this author Christina Jamieson More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...